GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Return-on-Tangible-Asset

Entheon Biomedical (XCNQ:ENBI) Return-on-Tangible-Asset : -71.15% (As of Nov. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Entheon Biomedical's annualized Net Income for the quarter that ended in Nov. 2023 was C$-0.30 Mil. Entheon Biomedical's average total tangible assets for the quarter that ended in Nov. 2023 was C$0.42 Mil. Therefore, Entheon Biomedical's annualized Return-on-Tangible-Asset for the quarter that ended in Nov. 2023 was -71.15%.

The historical rank and industry rank for Entheon Biomedical's Return-on-Tangible-Asset or its related term are showing as below:

XCNQ:ENBI' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -351.74   Med: -46.93   Max: -3.39
Current: -52.88

During the past 7 years, Entheon Biomedical's highest Return-on-Tangible-Asset was -3.39%. The lowest was -351.74%. And the median was -46.93%.

XCNQ:ENBI's Return-on-Tangible-Asset is ranked worse than
59.46% of 1554 companies
in the Biotechnology industry
Industry Median: -40.005 vs XCNQ:ENBI: -52.88

Entheon Biomedical Return-on-Tangible-Asset Historical Data

The historical data trend for Entheon Biomedical's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Return-on-Tangible-Asset Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -13.16 -8.25 -306.55 -351.74 -51.28

Entheon Biomedical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,297.35 -53.33 -23.13 -75.62 -71.15

Competitive Comparison of Entheon Biomedical's Return-on-Tangible-Asset

For the Biotechnology subindustry, Entheon Biomedical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Return-on-Tangible-Asset falls into.



Entheon Biomedical Return-on-Tangible-Asset Calculation

Entheon Biomedical's annualized Return-on-Tangible-Asset for the fiscal year that ended in Nov. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Nov. 2023 )  (A: Nov. 2022 )(A: Nov. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Nov. 2023 )  (A: Nov. 2022 )(A: Nov. 2023 )
=-0.3/( (0.769+0.401)/ 2 )
=-0.3/0.585
=-51.28 %

Entheon Biomedical's annualized Return-on-Tangible-Asset for the quarter that ended in Nov. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Nov. 2023 )  (Q: Aug. 2023 )(Q: Nov. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Nov. 2023 )  (Q: Aug. 2023 )(Q: Nov. 2023 )
=-0.296/( (0.431+0.401)/ 2 )
=-0.296/0.416
=-71.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Nov. 2023) net income data.


Entheon Biomedical  (XCNQ:ENBI) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Entheon Biomedical Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines